Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

Hepatocyte estrogen receptor alpha mediates estrogen action to promote reverse cholesterol transport during Western-type diet feeding.

Zhu L, Shi J, Luu TN, Neuman JC, Trefts E, Yu S, Palmisano BT, Wasserman DH, Linton MF, Stafford JM.

Mol Metab. 2018 Feb;8:106-116. doi: 10.1016/j.molmet.2017.12.012. Epub 2017 Dec 29.

2.

High-Density Lipoprotein Cholesterol Concentration and Acute Kidney Injury After Cardiac Surgery.

Smith LE, Smith DK, Blume JD, Linton MF, Billings FT 4th.

J Am Heart Assoc. 2017 Dec 9;6(12). pii: e006975. doi: 10.1161/JAHA.117.006975.

3.

Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry.

Amrock SM, Duell PB, Knickelbine T, Martin SS, O'Brien EC, Watson KE, Mitri J, Kindt I, Shrader P, Baum SJ, Hemphill LC, Ahmed CD, Andersen RL, Kullo IJ, McCann D, Larry JA, Murray MF, Fishberg R, Guyton JR, Wilemon K, Roe MT, Rader DJ, Ballantyne CM, Underberg JA, Thompson P, Duffy D, Linton MF, Shapiro MD, Moriarty PM, Knowles JW, Ahmad ZS.

Atherosclerosis. 2017 Dec;267:19-26. doi: 10.1016/j.atherosclerosis.2017.10.006. Epub 2017 Oct 6.

PMID:
29080546
4.

A case of severe acquired hypertriglyceridemia in a 7-year-old girl.

Lilley JS, Linton MF, Kelley JC, Graham TB, Fazio S, Tavori H.

J Clin Lipidol. 2017 Nov - Dec;11(6):1480-1484. doi: 10.1016/j.jacl.2017.08.003. Epub 2017 Aug 12.

PMID:
28916403
5.

Loss of SPRR3 in ApoE-/- mice leads to atheroma vulnerability through Akt dependent and independent effects in VSMCs.

Lietman CD, Segedy AK, Li B, Fazio S, Atkinson JB, Linton MF, Young PP.

PLoS One. 2017 Sep 8;12(9):e0184620. doi: 10.1371/journal.pone.0184620. eCollection 2017.

6.

Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia.

Beigneux AP, Miyashita K, Ploug M, Blom DJ, Ai M, Linton MF, Khovidhunkit W, Dufour R, Garg A, McMahon MA, Pullinger CR, Sandoval NP, Hu X, Allan CM, Larsson M, Machida T, Murakami M, Reue K, Tontonoz P, Goldberg IJ, Moulin P, Charrière S, Fong LG, Nakajima K, Young SG.

N Engl J Med. 2017 Apr 27;376(17):1647-1658. doi: 10.1056/NEJMoa1611930. Epub 2017 Apr 5.

7.

SR-BI: A Multifunctional Receptor in Cholesterol Homeostasis and Atherosclerosis.

Linton MF, Tao H, Linton EF, Yancey PG.

Trends Endocrinol Metab. 2017 Jun;28(6):461-472. doi: 10.1016/j.tem.2017.02.001. Epub 2017 Mar 1. Review.

PMID:
28259375
8.

Net cholesterol efflux capacity of HDL enriched serum and coronary atherosclerosis in rheumatoid arthritis.

Ormseth MJ, Yancey PG, Yamamoto S, Oeser AM, Gebretsadik T, Shintani A, Linton MF, Fazio S, Davies SS, Roberts LJ 2nd, Vickers KC, Raggi P, Kon V, Stein CM.

IJC Metab Endocr. 2016 Dec;13:6-11. doi: 10.1016/j.ijcme.2016.08.002. Epub 2016 Aug 28.

9.

Monoclonal antibodies that bind to the Ly6 domain of GPIHBP1 abolish the binding of LPL.

Hu X, Sleeman MW, Miyashita K, Linton MF, Allan CM, He C, Larsson M, Tu Y, Sandoval NP, Jung RS, Mapar A, Machida T, Murakami M, Nakajima K, Ploug M, Fong LG, Young SG, Beigneux AP.

J Lipid Res. 2017 Jan;58(1):208-215. doi: 10.1194/jlr.M072462. Epub 2016 Nov 15.

10.

Macrophage Apoptosis and Efferocytosis in the Pathogenesis of Atherosclerosis.

Linton MF, Babaev VR, Huang J, Linton EF, Tao H, Yancey PG.

Circ J. 2016 Oct 25;80(11):2259-2268. Epub 2016 Oct 8. Review.

11.

US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry.

Ahmad ZS, Andersen RL, Andersen LH, O'Brien EC, Kindt I, Shrader P, Vasandani C, Newman CB, deGoma EM, Baum SJ, Hemphill LC, Hudgins LC, Ahmed CD, Kullo IJ, Gidding SS, Duffy D, Neal W, Wilemon K, Roe MT, Rader DJ, Ballantyne CM, Linton MF, Duell PB, Shapiro MD, Moriarty PM, Knowles JW.

J Clin Lipidol. 2016 Sep-Oct;10(5):1223-9. doi: 10.1016/j.jacl.2016.07.011. Epub 2016 Aug 6.

12.

Loss of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 Confers Resistance to the Antiatherogenic Effects of Tumor Necrosis Factor-α Inhibition.

Zhu L, Giunzioni I, Tavori H, Covarrubias R, Ding L, Zhang Y, Ormseth M, Major AS, Stafford JM, Linton MF, Fazio S.

Arterioscler Thromb Vasc Biol. 2016 Aug;36(8):1483-95. doi: 10.1161/ATVBAHA.116.307736. Epub 2016 Jun 30.

13.

Jnk1 Deficiency in Hematopoietic Cells Suppresses Macrophage Apoptosis and Increases Atherosclerosis in Low-Density Lipoprotein Receptor Null Mice.

Babaev VR, Yeung M, Erbay E, Ding L, Zhang Y, May JM, Fazio S, Hotamisligil GS, Linton MF.

Arterioscler Thromb Vasc Biol. 2016 Jun;36(6):1122-31. doi: 10.1161/ATVBAHA.116.307580. Epub 2016 Apr 21.

14.

Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.

deGoma EM, Ahmad ZS, O'Brien EC, Kindt I, Shrader P, Newman CB, Pokharel Y, Baum SJ, Hemphill LC, Hudgins LC, Ahmed CD, Gidding SS, Duffy D, Neal W, Wilemon K, Roe MT, Rader DJ, Ballantyne CM, Linton MF, Duell PB, Shapiro MD, Moriarty PM, Knowles JW.

Circ Cardiovasc Genet. 2016 Jun;9(3):240-9. doi: 10.1161/CIRCGENETICS.116.001381. Epub 2016 Mar 24.

15.

Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis.

Ormseth MJ, Yancey PG, Solus JF, Bridges SL Jr, Curtis JR, Linton MF, Fazio S, Davies SS, Roberts LJ 2nd, Vickers KC, Kon V, Michael Stein C; TETRAD Investigators.

Arthritis Rheumatol. 2016 Sep;68(9):2099-105. doi: 10.1002/art.39675.

16.

Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.

Tavori H, Giunzioni I, Predazzi IM, Plubell D, Shivinsky A, Miles J, Devay RM, Liang H, Rashid S, Linton MF, Fazio S.

Cardiovasc Res. 2016 May 15;110(2):268-78. doi: 10.1093/cvr/cvw053. Epub 2016 Mar 15.

17.

Macrophage IKKα Deficiency Suppresses Akt Phosphorylation, Reduces Cell Survival, and Decreases Early Atherosclerosis.

Babaev VR, Ding L, Zhang Y, May JM, Lin PC, Fazio S, Linton MF.

Arterioscler Thromb Vasc Biol. 2016 Apr;36(4):598-607. doi: 10.1161/ATVBAHA.115.306931. Epub 2016 Feb 4.

18.

The Role of Lipids and Lipoproteins in Atherosclerosis.

Linton MF, Yancey PG, Davies SS, Jerome WGJ, Linton EF, Vickers KC.

In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2015 Dec 24.

19.

Local effects of human PCSK9 on the atherosclerotic lesion.

Giunzioni I, Tavori H, Covarrubias R, Major AS, Ding L, Zhang Y, DeVay RM, Hong L, Fan D, Predazzi IM, Rashid S, Linton MF, Fazio S.

J Pathol. 2016 Jan;238(1):52-62. doi: 10.1002/path.4630. Epub 2015 Nov 13.

20.

HDL: Beyond Atheroprotection.

Kon V, Linton MF.

J Am Soc Nephrol. 2016 Feb;27(2):341-4. doi: 10.1681/ASN.2015070793. Epub 2015 Aug 28. No abstract available.

21.

Uric acid correlates to oxidation and inflammation in opposite directions in women.

Wu SH, Shu XO, Milne G, Xiang YB, Zhang X, Cai Q, Fazio S, Linton MF, Chen H, Purdue M, Rothman N, Gao YT, Zheng W, Yang G.

Biomarkers. 2015;20(4):225-31. doi: 10.3109/1354750X.2015.1068852.

22.

Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.

Yamamoto S, Zhong J, Yancey PG, Zuo Y, Linton MF, Fazio S, Yang H, Narita I, Kon V.

Atherosclerosis. 2015 Sep;242(1):56-64. doi: 10.1016/j.atherosclerosis.2015.06.055. Epub 2015 Jul 4.

23.

Sex-Specific Parental Effects on Offspring Lipid Levels.

Predazzi IM, Sobota RS, Sanna S, Bush WS, Bartlett J, Lilley JS, Linton MF, Schlessinger D, Cucca F, Fazio S, Williams SM.

J Am Heart Assoc. 2015 Jun 30;4(7). pii: e001951. doi: 10.1161/JAHA.115.001951.

24.

Macrophage SR-BI mediates efferocytosis via Src/PI3K/Rac1 signaling and reduces atherosclerotic lesion necrosis.

Tao H, Yancey PG, Babaev VR, Blakemore JL, Zhang Y, Ding L, Fazio S, Linton MF.

J Lipid Res. 2015 Aug;56(8):1449-60. doi: 10.1194/jlr.M056689. Epub 2015 Jun 9.

25.
26.

Isolevuglandin-type lipid aldehydes induce the inflammatory response of macrophages by modifying phosphatidylethanolamines and activating the receptor for advanced glycation endproducts.

Guo L, Chen Z, Amarnath V, Yancey PG, Van Lenten BJ, Savage JR, Fazio S, Linton MF, Davies SS.

Antioxid Redox Signal. 2015 Jun 20;22(18):1633-45. doi: 10.1089/ars.2014.6078. Epub 2015 Mar 18.

27.

Macrophage apoAI protects against dyslipidemia-induced dermatitis and atherosclerosis without affecting HDL.

Tavori H, Su YR, Yancey PG, Giunzioni I, Wilhelm AJ, Blakemore JL, Zabalawi M, Linton MF, Sorci-Thomas MG, Fazio S.

J Lipid Res. 2015 Mar;56(3):635-43. doi: 10.1194/jlr.M056408. Epub 2015 Jan 15.

28.

Dysfunctional high-density lipoproteins in children with chronic kidney disease.

Kaseda R, Jabs K, Hunley TE, Jones D, Bian A, Allen RM, Vickers KC, Yancey PG, Linton MF, Fazio S, Kon V.

Metabolism. 2015 Feb;64(2):263-73. doi: 10.1016/j.metabol.2014.10.020. Epub 2014 Oct 25.

29.

Identification of small proline-rich repeat protein 3 as a novel atheroprotective factor that promotes adaptive Akt signaling in vascular smooth muscle cells.

Segedy AK, Pyle AL, Li B, Zhang Y, Babaev VR, Jat P, Fazio S, Atkinson JB, Linton MF, Young PP.

Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2527-36. doi: 10.1161/ATVBAHA.114.303644. Epub 2014 Oct 2.

30.

Macrophage deficiency of Akt2 reduces atherosclerosis in Ldlr null mice.

Babaev VR, Hebron KE, Wiese CB, Toth CL, Ding L, Zhang Y, May JM, Fazio S, Vickers KC, Linton MF.

J Lipid Res. 2014 Nov;55(11):2296-308. doi: 10.1194/jlr.M050633. Epub 2014 Sep 19.

31.

Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice.

Tavori H, Fan D, Giunzioni I, Zhu L, Linton MF, Fogo AB, Fazio S.

J Lipid Res. 2014 Oct;55(10):2073-81. doi: 10.1194/jlr.M049874. Epub 2014 Sep 2.

32.

Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.

Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I, Fazio S.

Circulation. 2014 Jul 29;130(5):431-41. doi: 10.1161/CIRCULATIONAHA.113.006720. Epub 2014 May 23. Erratum in: Circulation. 2015 May 5;131(18):e429.

33.

Response to Duell et al.

Tavori H, Giunzioni I, Linton MF, Fazio S.

Circ Res. 2014 Jun 20;115(1):e5. doi: 10.1161/CIRCRESAHA.114.304199. No abstract available.

34.

Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis.

Tavori H, Giunzioni I, Linton MF, Fazio S.

Circ Res. 2013 Dec 6;113(12):1290-5. doi: 10.1161/CIRCRESAHA.113.302655. Epub 2013 Oct 11.

35.

Oral retinoids and plasma lipids.

Lilley JS, Linton MF, Fazio S.

Dermatol Ther. 2013 Sep-Oct;26(5):404-10. doi: 10.1111/dth.12085. Review.

PMID:
24099071
36.

Killing two birds with one stone, maybe: CETP inhibition increases both high-density lipoprotein levels and insulin secretion.

Fazio S, Linton MF.

Circ Res. 2013 Jul 5;113(2):94-6. doi: 10.1161/CIRCRESAHA.113.301832. No abstract available.

37.

Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.

Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, Fazio S.

Circulation. 2013 Jun 18;127(24):2403-13. doi: 10.1161/CIRCULATIONAHA.113.001592. Epub 2013 May 20.

38.

When it looks like familial hypercholesterolemia...but is not.

Fazio S, Linton MF.

Circ Cardiovasc Genet. 2012 Dec;5(6):599-601. doi: 10.1161/CIRCGENETICS.112.965137. No abstract available.

39.

Dysfunctional high-density lipoprotein in patients on chronic hemodialysis.

Yamamoto S, Yancey PG, Ikizler TA, Jerome WG, Kaseda R, Cox B, Bian A, Shintani A, Fogo AB, Linton MF, Fazio S, Kon V.

J Am Coll Cardiol. 2012 Dec 11;60(23):2372-9. doi: 10.1016/j.jacc.2012.09.013. Epub 2012 Nov 7.

40.

Free fatty acids are associated with metabolic syndrome and insulin resistance but not inflammation in systemic lupus erythematosus.

Ormseth MJ, Swift LL, Fazio S, Linton MF, Raggi P, Solus JF, Oeser A, Bian A, Gebretsadik T, Shintani A, Stein CM.

Lupus. 2013 Jan;22(1):26-33. doi: 10.1177/0961203312462756. Epub 2012 Oct 11.

41.

Proprotein convertase subtilisin/kexin type 9 as transducer of physiologic influences on cellular cholesterol: a case for resistin.

Fazio S, Linton MF.

J Am Coll Cardiol. 2012 May 8;59(19):1706-8. doi: 10.1016/j.jacc.2012.01.034. No abstract available.

42.

Inhibition of apolipoprotein(a) synthesis by farnesoid X receptor and fibroblast growth factor 15/19: a step toward selective lipoprotein(a) therapeutics.

Fazio S, Linton MF.

Arterioscler Thromb Vasc Biol. 2012 May;32(5):1060-2. doi: 10.1161/ATVBAHA.112.245571. No abstract available.

43.

Benzo[a]pyrene potentiates the pathogenesis of abdominal aortic aneurysms in apolipoprotein E knockout mice.

Prins PA, Perati PR, Kon V, Guo Z, Ramesh A, Linton MF, Fazio S, Sampson UK.

Cell Physiol Biochem. 2012;29(1-2):121-30. doi: 10.1159/000337593. Epub 2012 Mar 1.

44.

Dyslipidemias in children.

Lilley JS, Linton MF, Fazio S.

Pediatr Ann. 2012 Feb 8;41(2):e1-7. doi: 10.3928/00904481-20120110-08. No abstract available.

PMID:
22299622
45.

Low levels of high-density lipoprotein cholesterol due to lecithin:cholesterol acyltransferase mutations increase carotid atherosclerosis.

Fazio S, Linton MF.

J Am Coll Cardiol. 2011 Dec 6;58(24):2488-90. doi: 10.1016/j.jacc.2010.11.091. No abstract available.

46.

Evaluation of macrophage-specific promoters using lentiviral delivery in mice.

Levin MC, Lidberg U, Jirholt P, Adiels M, Wramstedt A, Gustafsson K, Greaves DR, Li S, Fazio S, Linton MF, Olofsson SO, Borén J, Gjertsson I.

Gene Ther. 2012 Nov;19(11):1041-7. doi: 10.1038/gt.2011.195. Epub 2011 Dec 1.

47.

Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges.

Sampson UK, Fazio S, Linton MF.

Curr Atheroscler Rep. 2012 Feb;14(1):1-10. doi: 10.1007/s11883-011-0219-7. Review.

48.

Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein.

Du F, Hui Y, Zhang M, Linton MF, Fazio S, Fan D.

J Biol Chem. 2011 Dec 16;286(50):43054-61. doi: 10.1074/jbc.M111.273474. Epub 2011 Oct 25.

49.

Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis.

Yamamoto S, Yancey PG, Zuo Y, Ma LJ, Kaseda R, Fogo AB, Ichikawa I, Linton MF, Fazio S, Kon V.

Arterioscler Thromb Vasc Biol. 2011 Dec;31(12):2856-64. doi: 10.1161/ATVBAHA.111.237198. Epub 2011 Oct 6.

50.

Free fatty acids are associated with insulin resistance but not coronary artery atherosclerosis in rheumatoid arthritis.

Ormseth MJ, Swift LL, Fazio S, Linton MF, Chung CP, Raggi P, Rho YH, Solus J, Oeser A, Bian A, Gebretsadik T, Shintani A, Stein CM.

Atherosclerosis. 2011 Dec;219(2):869-74. doi: 10.1016/j.atherosclerosis.2011.09.005. Epub 2011 Sep 12.

Supplemental Content

Loading ...
Support Center